Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes

References

• Alexander GC, Sehgal NL, Moloney RM, et al. National trends in the treatment of type 2 diabetes mellitus, 1994 − 2007. Arch Intern Med 2008;168:2088-94
   PubMed Web of Science ®Google Scholar
• Economic Costs of Diabetes in the US in 2007. Diabetes Care 2008;31:596-615
   Google Scholar
• Morsanutto A, Berto P, Lopatriello S, et al. Major complications have an impact on total annual medical cost of diabetes: results of a database analysis. J Diabetes Complications. 2006;20:163-9
   PubMed Web of Science ®Google Scholar
• Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm 2006;12:130-42
   PubMed Web of Science ®Google Scholar
• Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm 2003;9:309-16
   PubMedGoogle Scholar
• Schmoelzer I, de Campo A, Pressl H, et al. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2005;113:176-81
   PubMed Web of Science ®Google Scholar
• McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002;24:530-9
   PubMed Web of Science ®Google Scholar
• Tamemoto H, Ikoma A, Saitoh T, et al. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes. Diabetes Technol Ther 2007;9:246-53
   PubMed Web of Science ®Google Scholar
• Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307-13
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
   PubMed Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V, et al. on behalf of the IMPROVE™ Study Group Expert Panel. Initiating insulin therapy with, or switching insulin therapy to, biphasic insulin aspart 30/70 (Novomix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the ImproveTM observational study. Int J Clin Pract 2009;63:522-31
   PubMed Web of Science ®Google Scholar
• Khutsoane D, Sharma SK, Almustafa M, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008;10:212-22
   PubMed Web of Science ®Google Scholar
• Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26:531-40
   PubMed Web of Science ®Google Scholar
• Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:2075-283
   Google Scholar
• Malone JK, Kerr LF, Campaigne BN, et al. Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-44
   PubMed Web of Science ®Google Scholar
• Jang HC, Guler S, Shestakova M. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008;62:1013-18
   PubMed Web of Science ®Google Scholar
• Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008;149:549-59
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians, 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG66FullGuideline0509.pdf [Last accessed 18 September 2009]
   Google Scholar
• Goodall G, Jendle JH, Valentine WJ, et al. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: the long-term health economic implications in a Swedish setting. Int J Clin Pract 2008;62:869-76
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes Obes Metab 2007;9:103-13
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005;21:2063-71
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes, UK Prospective Diabetes Study (UKPDS): the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl. 1):S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl. 1):S27-40
   PubMed Web of Science ®Google Scholar
• Hayes RP, Bowman L, Monahan PO, et al. Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. Diabetes Educ 2006;32:404-14
   PubMed Web of Science ®Google Scholar
• Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307-13
   PubMed Web of Science ®Google Scholar
• Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin 2007;23:3209-14
   PubMed Web of Science ®Google Scholar
• Boehm BO, Vaz JA, Brondsted L, et al. Long term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004;15:496-502
   PubMedGoogle Scholar
• Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human?. Diabetes Obes Metab 2007;9:630-9
   PubMed Web of Science ®Google Scholar
• Palmer JL, Gibbs M, Scheijbeler HW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008;25:752-74
   PubMed Web of Science ®Google Scholar
• Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value Health 2008;11(Suppl. 1):S43-51
   PubMedGoogle Scholar
• Barzi F, Patel A, Gu D, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007;61:115-21
   PubMed Web of Science ®Google Scholar
• Ali M, White J, Lee CH, et al. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ 2008;11:651-70
   PubMedGoogle Scholar
• Lee HK, Seo SJ, Smith-Palmer J, et al. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea. Value Health 2009;12(Suppl. 3):S55-61
   PubMedGoogle Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009;12:409-18
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2009 Apr 20 [Epub ahead of publication]
   Google Scholar
• Manca A, Willan AR. ‘Lost in translation’: accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006;24:1101-19
   PubMed Web of Science ®Google Scholar
• Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009;52:1990-2000
   Google Scholar
• Palmer A, Roze S, Nicklasson L et al. Estimating the cost-effectiveness in the US of biphasic insulin aspart 70/30 vs. insulin glargine over the INITIATE trial patients estimated lifespan. American Diabetes Association 65th Scientific Session (2005) Abstract number 2543-PO
   Google Scholar
• Ray J, Munro V, Brandt AS et al. Cost-effectiveness of insulin therapy in type 2 diabetes patients comparing biphasic insulin aspart 70/30 versus insulin glargine in the Swedish setting. American Diabetes Association. 66th Scientific Session (2006) Abstract number 2411-PO
   Google Scholar
• Valentine W, Cobden D, and Palmer A. Randomized initiation of biphasic or basal analog insulin among type 2 diabetes patients: an economic comparison. American Diabetes Association 66th Scientific Sessions (2006) Abstract number 2376-PO
   Google Scholar
• Lynch M, Scheijbeler H, Valentine WJ et al. Cost-effectiveness of biphasic insulin aspart 30 versus biphasic human insulin for type 2 diabetes patients in China. ISPOR 2007 10th Annual European Congress. Poster number PDB27
   Google Scholar
• Aristides M, Kotchie RW, Nielsen S et al. Cost-effectiveness of biphasic insulin aspart 30 versus biphasic human insulin for type 2 diabetes in a Polish setting. ISPOR 2007 10th Annual European Congress. Poster number PDB23
   Google Scholar
• Tucker DMD, Valentine WJ, Nielsen S et al. Evaluating the cost-effectiveness of biphasic insulin aspart 30 versus biphasic human insulin for the treatment of type 2 diabetes in the Spanish setting. ISPOR 2007 10th Annual European Congress. Poster number PDB30
   Google Scholar
• White J, Aagren M, Jing L. Cost-utility analysis of biphasic insulin aspart versus human insulin in type 2 diabetes mellitus patients treated in tier III hospitals in Beijing, China: a long term outcomes model evaluation from the IMPROVE observational study. ISPOR 2008 11th Annual European Congress. Poster number PBD35
   Google Scholar
• Aagren M, Thomsen TL, Knudsen VK. Projected cost-effectiveness of biphasic insulin aspart in type 2 diabetes patients switched from biphasic human insulin in the United States. ISPOR 2009 14th Annual International Meeting. Oral presentation number DB1
   Google Scholar
• Ali M, White J, Nielsen S et al. Cost-effectiveness analysis of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in Saudi Arabia. ISPOR 2008 3rd Asia-Pacific Conference. Poster number PDB3
   Google Scholar
• White J, Stoustrup M and Aagren M. Cost-effectiveness analysis of human premix insulin regimens compared with a premix analogue insulin in the private health care sector in South Africa. ISPOR 2008 11th Annual European Congress. Poster number PDB25
   Google Scholar